Cell Therapy Manufacturing

Cell Therapy Manufacturing - External Quality Assurance (QA) AssociateNexcella, Inc.Sao Paulo / HybridOur 3 Core Values IntelligenceIntegrityInitiativeWhat You'll Do The Specialist, External Quality Assurance (EQA) will provide oversight of Contract Development and Manufacturing Organizations (CDMOs) and testing laboratories to ensure compliance with c GMP, regulatory requirements, and company quality standards. This role is critical in supporting ongoing manufacturing campaigns, batch release, and ensuring timely resolution of quality events.Key ResponsibilitiesReview and approve deviations, Out-of-Specification (OOS) investigations, CAPAs, and change controls from CDMOs and external testing laboratories.Monitor manufacturing campaigns, production activities, and resolve issues during routine manufacturing.Review and approve QC/analytical results and Certificates of Analysis from CDMOs/external labs.Review and approve production lot records for compliance prior to disposition.Perform GMP reviews of incoming documentation (batch records, test data, release packages).Ensure timely escalation and resolution of manufacturing and quality issues.Collaborate with internal cross-functional teams (QA, QC, Supply Chain, Regulatory, CMC) to ensure readiness for release and regulatory filings.Support audit readiness activities for Regulatory Authority inspections.QualificationsBachelor's degree in Life Sciences, Chemistry, Biochemistry, Engineering, or related discipline.3–5 years of QA experience in the biopharmaceutical or cell/gene therapy industry.Strong knowledge of c GMP, ICH Q7/Q10, FDA 21 CFR Parts *******.Experience with CDMO oversight, lot release, and deviation management.Excellent communication and problem-solving skills.About Nexcella, Inc.Nexcella, Inc. is a subsidiary of Immix Biopharma, Inc. (Immix Bio) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a "digital filter" that filters out non-specific activation. NXC-201 is being evaluated in the U. S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT********), with a registrational design. Interim results were presented at ASCO **** in an oral presentation by Heather Landau, M. D. of Memorial Sloan Kettering Cancer Center. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA. Learn more at and Be Proactive In AL.com.